Relationships of urinary VEGF/CR and IL-6/CR with glomerular pathological injury in asymptomatic hematuria patients

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 356-362

  Ma, Lu ^a   Gao, Yinghe ^a   Chen, Guanglei ^a   Gong, Junhua ^a   Yang, Dan ^a   Xie, Yongxin ^a   Wang, Mingcui ^a   Chen, Hong ^a   Song, Minghui ^a  

^a Integrated Chinese and Western Medicine Treatment of Renal Disease Centre   (China)

Author keywords

Cytokine receptor gp130; Hematuria; Kidney glomerulus; Vascular endothelial growth factor a

Indexed keywords

4 [3 (1H TETRAZOL 5 YL) 8 COUMARINYLOXY] BUTYRIC ACID; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C3C; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6; UNCLASSIFIED DRUG; VASCULOTROPIN; CREATININE; GLYCOPROTEIN GP 130; IL6 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; B SCAN; CASE CONTROL STUDY; CELL DAMAGE; CELL PROLIFERATION; CREATININE URINE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOGEN BLOOD LEVEL; GLOMERULAR PATHOLOGICAL INJURY; HEMATURIA; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; PROTEIN URINE LEVEL; PROTEINURIA; SCORING SYSTEM; URINALYSIS; BIOPSY; GLOMERULUS; KIDNEY DISEASE; METABOLISM; PATHOLOGY; URINE;

BIOPSY; CASE-CONTROL STUDIES; CREATININE; CYTOKINE RECEPTOR GP130; HEMATURIA; HUMANS; INTERLEUKIN-6; KIDNEY DISEASES; KIDNEY GLOMERULUS; PROTEINURIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922351489     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892085     Document Type: Article

References (27)

1. Chow KM, Kwan BC, Li PK, Szeto CC: Asymptomatic isolated microscopic haematuria: long-term follow-up. QJM, 2004; 97: 739–45
2. Kincaid-Smith P, Fairley K: The investigation of hematuria. Semin Nephrol, 2005; 25: 127–35
3. Jimbo M: Evaluation and management of hematuria. Prim Care, 2010; 37: 461–72
4. Kaden J, Priesterjahn R: Increasing urinary IL-6 levels announce kidney graft rejection. Transpl Int, 2000; 13: S34–41
5. Kielar ML, John R, Bennett M et al: Maladaptive role of IL-6 in ischemic acute renal failure. J Am Soc Nephrol, 2005; 16: 3315–25
6. Fukatsu A, Matsuo S, Tamai H et al: Distribution of interleukin-6 in normal and diseased human kidney. Lab Invest, 1991; 65: 61–66
7. Del Porto F, Mariotti A, Ilardi M et al: Kidney vasculogenesis and angiogenesis: role of vascular endothelial growth factor. Eur Rev Med Pharmacol Sci, 1999; 3: 149–53
8. Hanaoka M, Droma Y, Naramoto A et al: Vascular endothelial growth factor inpatients with high-altitude pulmonary edema. J Appl Physiol (1985), 2003; 94: 1836–40
9. Hirschberg R, Wang S, Mitu GM: Functional symbiosis between endothelium and epithelial cells inglomeruli. Cell Tissue Res, 2008; 331: 485–93
10. Satchell SC, Anderson KL, Mathieson PW: Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol, 2004; 15: 566–74
11. Doi K, Noiri E, Fujita T: Role of vascular endothelial growth factor in kidney disease. Curr Vasc Pharmacol, 2010; 8: 122–28
12. Donadio JV, Bergstralh EJ, Offord KP et al: Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Mayo Nephrology Collaborative Group. Clin Nephrol, 1994; 41: 65–71
13. Alarnarline E, Sabatier JC, Bertboux FC: Comparison of pathological lesion on repeated biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis. Clin Nephrol, 1990; 34(2): 45–51
14. Okada H, Suzuki H, Konishi K et al: Histological alteration in renal specimens as indicators of prognosis of IgA nephropathy. Clin Nephrol, 1992; 37: 235–38
15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002; 39: S1–266
16. Song M, Ma L, Yang D et al: Clinical values of urinary IL-6 in asymptomatic renal hematuria and renal hematuria with proteins. Exp Ther Med, 2013; 6: 396–400
17. Abbott F, Rvan JJ, Ceska M et al: Interleukin-1 beta stimulates human mesangial cells to synthesize and release interleukins-6 and -8. Kindy Int, 1991; 40: 597–605
18. Ng DP, Nurbaya S, Ye SH, Krolewski AS: An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients. Kidney Int, 2008; 74: 521–27
19. Taniguchin Y, yorioka N, Oda H, Yamakido M: Platelet-derived growth factor, interleukin (IL)-1b, IL-6R and tumor necrosis factor-a in IgA nephropathy. An immunohistochemical study. Nephron, 1996; 74: 652–60
20. Mantovani A, Bussolino F, Introna M: Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today, 1997; 18: 231–40
21. Inci MF, Ozkan F, Bozkurt S et al: Correlation of volume, position of stone, and hydronephrosis with microhematuria in patients with solitary urolithiasis. Med Sci Monit, 2013; 19: 295–99
22. Haas CS, Câmpean V, Kuhlmann A et al: Analysis of glomerular VEGF mRNA and protein expression in murine mesangioproliferative glomerulonephritis. Virchows Arch, 2007; 450: 81–92
23. Wei LH, Kuo ML, Chen CA et al: Interleukin-6 promotes cervical tumor growth by VEGF- dependent angiogenesis via a STAT3 pathway. Oncogene, 2003; 22: 1517–27
24. Cohen T, Nahari D, Cerem LW et al: Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem, 1996; 271: 736–41
25. Topaloglu R, Sungur A, Baskin E et al: Vescular endothelial growth factor in Henoch-Schonlein purpura. J Rheumatol, 2001; 28: 2269–73
26. Wake M, Hamada Y, Kumagai K et al: Up-regulation of interleukin-6 and vascular endothelial growth factor-A in the synovial fluid of temporomandibular joints affected by synovial chondromatosis. Br J Oral Maxillofac Surg, 2013; 51: 164–69
27. Gentiletti J, Fava RA: Does vascular endothelial growth factor play a role in interleukin-6 receptor antagonist therapy for rheumatoid arthritis? Arthritis Rheum, 2003; 48: 1471–74